The FDA approved lenacapavir, a new drug providing nearly complete HIV protection with biannual injections. It shows high effectiveness across diverse high-risk populations. Long-acting injections are likely to improve adherence and accessibility compared to daily oral PrEP. Historical efforts for HIV prevention focused on behavior and barrier strategies but were insufficient. A shift towards biomedical prevention began in 2010 with key clinical trial findings emphasizing medication use for preventing and managing HIV infections. Ongoing health system adaptations are necessary to facilitate long-acting PrEP implementation.
Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. This long-acting injectable has shown effectiveness across diverse high-risk populations, surpassing adherence issues found with daily oral PrEP.
Health systems must adapt to deliver long-acting PrEP amid significant cuts to government health insurance and programs. The evolution of HIV prevention strategies signals a shift towards biomedicine as a solution.
Collection
[
|
...
]